for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Westlaw News

IN BRIEF: Judge denies Coherus fees in Neulasta patent fight with Amgen

Coherus BioSciences, which last year introduced a biosimilar version of Amgen’s oncology drug Neulasta, cannot recover attorneys’ fees for defeating Amgen’s patent-infringement lawsuit, U.S. District Judge Leonard Stark held Monday in Delaware.

Coherus’ counsel at Morris James had argued that this was an exceptional case, warranting fees, because Amgen had pursued a baseless claim and appeal “to the bitter end,” which Coherus said was intended to thwart competition by “nascent … financially disadvantaged” biosimilar manufacturers.

To read the full story on Westlaw Today, click here: bit.ly/3fVUOtM

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up